

Reversible nasal airway obstruction: does change in nasal peak inspiratory flow following decongestion predict response to topical steroids in chronic rhinosinusitis patients?

N K F KOO NG¹, D YOUNG², G W McGARRY¹

¹Department of Otolaryngology and Head and Neck Surgery, Glasgow Royal Infirmary, and ²Department of Mathematics and Statistics, University of Strathclyde, Glasgow, Scotland, UK

Abstract

Background: Predicting which chronic rhinosinusitis patients have nasal obstruction due to reversible mucosal inflammation could prevent unnecessary surgery.

Aim: To investigate whether the change in nasal peak inspiratory flow following maximal decongestion (i.e. mucosal reversibility) at first visit predicts the response to topical steroids in chronic rhinosinusitis patients, as measured by the 22-item Sinonasal Outcome Test.

Methods: Prospective study of 128 consecutive new adult patients presenting with nasal obstruction due to chronic rhinosinusitis (January 2008 to July 2010). The 22-item Sinonasal Outcome Test questionnaire was administered and the nasal peak inspiratory flow assessed. Following maximal nasal decongestion, the nasal peak inspiratory flow was again tested and the difference calculated. Topical steroids were administered for at least six weeks. The 22-item Sinonasal Outcome Test was then repeated and the difference calculated.

Results: Data were analysed using means and correlation studies (Spearman's rank correlation). There was no correlation between the pre- versus post-decongestion nasal peak inspiratory flow difference and the pre- versus post-steroid 22-item Sinonasal Outcome Test difference, in chronic rhinosinusitis patients with or without nasal polyps.

Conclusion: The difference between pre- and post-decongestion nasal peak inspiratory flow does not predict chronic rhinosinusitis patients' response to topical steroids.

Key words: Nasal Obstruction; Rhinitis; Sinusitis; Nasal Decongestants; Steroids

Introduction

Chronic rhinosinusitis is a common disorder of multifactorial origin involving inflammation of the mucosa of the nose and paranasal sinuses.¹ It would be useful, in everyday clinical practice, to be able to identify those chronic rhinosinusitis patients whose nasal obstruction includes a significant reversible mucosal component, as these patients may be more likely to respond to medical therapy.

Rhinomanometry, although considered to be the 'gold standard' for assessing nasal resistance,² is impractical for routine use in the out-patient setting. Nasal peak inspiratory flow (NPIF) is a more readily available alternative which can easily be used in out-patients, and which has been shown to have a reasonable correlation with rhinomanometry.³ Nasal peak inspiratory flow measures the highest airflow achieved through both nostrils during maximal forced nasal inspiration, and is fast, simple and cheap.

The change in NPIF following nasal decongestion, due to vasoconstriction and shrinkage of the nasal mucosa, provides an objective measure of the reversible mucosal component of nasal resistance. Patients with bony or cartilaginous deformities respond poorly to decongestants; diagnostic decongestion can therefore help to differentiate mucosal from structural components of nasal resistance.⁴ One would expect that chronic rhinosinusitis patients with a greater change in NPIF following decongestion (implying a greater reversible mucosal component of nasal resistance) would respond better to the anti-inflammatory effects of topical nasal steroids. This should lead to a corresponding reduction in the 22-item Sinonasal Outcome Test score; this questionnaire is currently considered the ideal patient-centred outcome tool for chronic rhinosinusitis,⁵ and includes a question on nasal blockage.

Our aim was to investigate this hypothetical correspondence further, by assessing whether the change

in NPIF following maximal decongestion at first visit could predict the response to topical steroids, as measured by the 22-item Sinonasal Outcome Test, in patients with chronic rhinosinusitis.

Methods

We analysed our prospectively updated, computerised database and we reviewed our case notes for consecutive new adult patients (above 18 years of age) who presented with nasal obstruction due to chronic rhinosinusitis with and without polyps at Glasgow Royal Infirmary between January 2008 and July 2010.

We excluded the following patients: those who had taken a prolonged course of steroids prior to their first clinic visit (more than six weeks); those with previous sinonasal surgery; those with unilateral nasal obstruction; those with a significant, fixed, visible skeletal nasal deformity (e.g. deviated nasal septum); and those with a pre-decongestion NPIF of more than 120 l/min (considered to be the cut-off threshold between normal and pathological airflow).⁴

Each patient was asked to complete the 22-item Sinonasal Outcome Test, and at their first clinic visit was assessed by a clinician and examined using rigid nasal endoscopy. In those patients whose main complaint was nasal obstruction thought to result from chronic rhinosinusitis with or without nasal polyps, NPIF was measured using a Youlten meter (Clement Clarke, London, UK), following a standardised protocol. The patient was asked to apply the face mask, obtaining an airtight seal, and then to inspire through the nose, following which the maximal flow rate was read from the meter. The highest of three readings was recorded.

A standardised protocol was then followed to maximally decongest the nose, by applying two puffs of lidocaine hydrochloride 5 per cent and phenylephrine hydrochloride 0.5 per cent topical solution to each nostril. After 10 minutes, the NPIF was reassessed, again recording the highest of three readings. The change in NPIF following nasal decongestion was then calculated by subtracting the pre-decongestion NPIF from the post-decongestion NPIF.

Patients were prescribed regular topical nasal steroids for at least six weeks, continuing until review within three months of initial assessment. Patients with polyps were given betamethasone nasal drops (two drops twice daily in each nostril), and those without polyps were given mometasone nasal spray (two puffs once daily in each nostril).

Each patient was reviewed six weeks to three months after their initial assessment. At this review, the 22-item Sinonasal Outcome Test was re-administered and the difference in questionnaire scores calculated by subtracting the post-steroid score from the pre-steroid score.

The change in NPIF following nasal decongestion and the change in 22-item Sinonasal Outcome Test score following steroid treatment were statistically analysed and the correlation between these two parameters assessed, including calculation of Spearman's rank

correlation. Patients with polyps were analysed separately from those without polyps.

Results

There were 128 chronic rhinosinusitis patients who fulfilled the inclusion criteria, all with complete data, of whom 51 patients (39.9 per cent) had polyps and 77 patients (60.1 per cent) did not (Table I).

Correlation studies showed no relationship between the change in NPIF following decongestion and the change in 22-item Sinonasal Outcome Test score following steroid treatment, based on absolute values for chronic rhinosinusitis patients with polyps (Spearman rank coefficient = 0.088, $p = 0.533$) (Figure 1) and without polyps (Spearman rank coefficient = -0.031 , $p = 0.789$) (Figure 2).

Analysis was also performed based on percentage changes of the same two parameters. Similarly, no correlation was found, either for patients with polyps (Spearman rank coefficient = -0.010 , $p = 0.945$) or without polyps (Spearman rank coefficient = 0.007, $p = 0.950$).

Discussion

These results show that the observed change in NPIF following maximal nasal decongestion at the first visit did not predict subsequent response to topical steroids as measured by the 22-item Sinonasal Outcome Test, in chronic rhinosinusitis patients both with and without polyps. Overall, our patients showed an increase in mean NPIF (from 61.0 to 74.5 l/min) following decongestion at first visit, indicating that they had an element of mucosal reversibility. Likewise, there was overall a corresponding improvement in sinonasal symptom scores, with a mean 22-item Sinonasal Outcome Test score reduction of 8.9 following a course of topical nasal steroids; however, we were unable to predict the response of individual patients.

Some authors have found a strong positive correlation between NPIF and the subjective sensation of nasal obstruction (as assessed by patient questionnaires).⁶ However, others have reported that subjective and objective measurements of nasal obstruction do not

TABLE I
CHRONIC RHINOSINUSITIS PATIENT DATA

Parameter	Polyps*	No polyps [†]	Total [‡]
NPIF (mean; l/min)			
– Pre-decong	62.7	59.3	61.0
– Post-decong	77.5	71.4	74.5
ΔNPIF	14.7	12.1	13.4
SNOT-22 score (mean)			
– Pre-steroid	38.8	50.3	44.6
– Post-steroid	31.8	39.5	35.7
ΔSNOT-22**	7.0	10.8	8.9

* $n = 51$; [†] $n = 77$; [‡] $n = 128$. **Absolute value. NPIF = nasal peak inspiratory flow; ΔNPIF = post-decongestion NPIF – pre-decongestion NPIF; SNOT-22 = 22-item Sinonasal Outcome Test; ΔSNOT-22 = pre-steroid SNOT-22 score – post-steroid SNOT-22 score




FIG. 1

Change in nasal peak inspiratory flow (Δ NPIF) versus change in 22-item Sinonasal Outcome Test score (Δ SNOT-22; absolute values) for chronic rhinosinusitis patients with polyps.




FIG. 2

Change in nasal peak inspiratory flow (Δ NPIF) versus change in 22-item Sinonasal Outcome Test (Δ SNOT-22; absolute values) in chronic rhinosinusitis patients without polyps.

always correlate.⁷ This study was based on changes, rather than absolute values, in NPIF and SNOT-22 in individual patients so this would have been less of a factor. However, we found wide inter-patient variation in the NPIF change following decongestion and the 22-item Sinonasal Outcome Test score change following steroid treatment. For example, one chronic rhinosinusitis patient without polyps had a post-decongestion NPIF change of 70 l/min but a post-steroid symptom score change of only 3, whereas another patient had corresponding changes of 0 l/min and 49.

- Identifying chronic rhinosinusitis patients with reversible nasal obstruction could prevent unneeded surgery
- Change in nasal peak inspiratory flow (NPIF) following decongestion can provide an objective measure of mucosal reversibility
- In this study, post-decongestion NPIF change did not predict symptomatic response to topical steroids
- Thus, NPIF measurement does not appear valuable in this setting

Following nasal decongestion, surprisingly, a few patients showed a decrease in NPIF. This parameter has been shown to be highly reproducible (although

there is a training effect between the first and second NPIF readings,² hence our use of the best of three readings), so the observed increase in nasal resistance post-decongestion in these few patients is not easily explainable. Conversely, following their course of topical steroids some patients had a higher 22-item Sinonasal Outcome Test score, suggesting that their symptoms had worsened during the six weeks to three months after their initial consultation. This was found for patients both with and without polyps, and with a wide range of post-decongestion NPIF changes; thus, it was not possible to predict which patients would report worse symptoms.

Likewise, in their smaller study of 31 allergic rhinitis patients, Barnes *et al.*⁸ found no correlation between acute response to xylometazoline decongestion and chronic response to mometasone furoate, as measured by NPIF, nasal forced inspiratory volume in 1 second, and nasal blockage score (using a 4-point scale from 0 to 3). This result agrees with our finding that, in chronic rhinosinusitis patients, the change in NPIF following maximal nasal decongestion at first visit did not predict response to topical steroids as measured by the 22-item Sinonasal Outcome Test and suggests that predicting subjective response to medical therapy in chronic rhinosinusitis is more complex.

References

- 1 Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. *Rhinol Suppl* 2007;**20**:1–136
- 2 Starling-Schwanz R, Peake HL, Salome CM, Toelle BG, Ng KW, Marks GB *et al.* Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis. *Allergy* 2005;**60**:795–800
- 3 Holmstrom M, Scadding GK, Lund VJ, Darby YC. Assessment of nasal obstruction. A comparison between rhinomanometry and nasal inspiratory peak flow. *Rhinology* 1990;**28**:191–6
- 4 Bermuller C, Kirsche H, Rettinger G, Riechelmann H. Diagnostic accuracy of peak nasal inspiratory flow and rhinomanometry in functional rhinosurgery. *Laryngoscope* 2008;**118**:605–10
- 5 Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. *Clin Otolaryngol* 2009;**34**:447–54
- 6 Fairley JW, Durham LH, Eil SR. Correlation of subjective sensation of nasal patency with nasal inspiratory peak flow rate. *Clin Otolaryngol Allied Sci* 1993;**18**:19–22
- 7 Morrissey MS, Alun-Jones T, Hill J. The relationship of peak inspiratory airflow to subjective airflow in the nose. *Clin Otolaryngol Allied Sci* 1990;**15**:447–51
- 8 Barnes ML, Bialosterski BT, Gray RD, Fardon TC, Lipworth BJ. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. *Rhinology* 2005;**43**:291–5

Address for correspondence:

Dr N K F Koo Ng,
Department of Otolaryngology and Head and Neck Surgery,
Glasgow Royal Infirmary,
16 Alexandra Parade,
Glasgow G31 2ER, Scotland, UK

Fax: +44 (0)141 211 5545
E-mail: nigel12@doctors.org.uk

Dr N K F Koo Ng takes responsibility for the integrity of the content of the paper
Competing interests: None declared